CRT-D is being evaluated to determine if it reduces mortality and heart failure events by 25% in patients with NYHA class I-II cardiomyopathy, EF ≤0.30, and QRS ≥130 ms.
Absolute Event Rate: 0% vs 0%
The planned MADIT-CRT trial is designed to determine if CRT-D will reduce the risk of mortality and HF events by approximately 25% in subjects with ischemic (NYHA class I-II) and non-ischemic (NYHA class II) cardiomyopathy, left ventricular dysfunction (EFor=130 ms).
Moss et al. (Sat,) reported a other. CRT-D is being evaluated to determine if it reduces mortality and heart failure events by 25% in patients with NYHA class I-II cardiomyopathy, EF ≤0.30, and QRS ≥130 ms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: